z-logo
open-access-imgOpen Access
Fear as a Barrier to Asymptomatic Colonoscopy Screening in an Urban Minority Population with Health Insurance
Author(s) -
Corey H. Basch,
Charles E. Basch,
Patricia Zybert,
Randi L. Wolf
Publication year - 2016
Publication title -
journal of community health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.822
H-Index - 63
eISSN - 1573-3610
pISSN - 0094-5145
DOI - 10.1007/s10900-016-0159-9
Subject(s) - asymptomatic , colonoscopy , medicine , population , health insurance , environmental health , family medicine , psychology , political science , health care , cancer , pathology , colorectal cancer , law
This study identified barriers to colonoscopy in a high-risk population and examined associations between barriers and both intention to comply with physician recommendation to receive colonoscopy and documented receipt of colonoscopy. Participants, enrollees in a randomized controlled trial assessing the effectiveness of educational interventions to promote colorectal cancer screening, were all 50+ years old and out of compliance with recommended screening guidelines. Direct financial cost of the procedure was not a barrier. The most commonly cited barriers were being afraid of the colonoscopy procedure (43.1 %), embarrassment (42.3 %), having to take a powerful laxative (36.2 %), fear of cancer (31.2 %), and fear of sedation (30.3 %). There were dose-response relationships between barriers and both intention to comply with physician recommendation of colonoscopy: 0, 1, 2, 3 barriers, 88.9, 79.0, 69.2 and 60.0 % intending to comply, respectively (linear trend χ(2) = 27.9, p = .000) and documented receipt of a colonoscopy: 0, 1, 2, 3 barriers, 21.7, 21.6, 8.5, 12.0 %, respectively (linear trend χ(2) = 8.4, p = .004). Only 6.9 % of the 102 expressing both fear of procedure and concern about taking a powerful laxative had a colonoscopy. These findings highlight the need to address patients' fear and suggest the importance of offering alternative colorectal cancer screening tests. ClinicalTrials.gov Identifier: NCT02392143.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom